title: The discovery of AZD9164, a novel muscarinic M3 antagonist.
abstract: The optimization of a new series of muscarinic M(3) antagonists is described, leading to the identification of AZD9164 which was progressed into the clinic for evaluation of its potential as a treatment for COPD.
authors: Department of Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, UK. antonio.mete@astrazeneca.com
authors: Antonio
authors: A
authors: Mete
authors: Keith
authors: K
authors: Bowers
authors: Eric
authors: E
authors: Chevalier
authors: David K
authors: DK
authors: Donald
authors: Helen
authors: H
authors: Edwards
authors: Katherine J
authors: KJ
authors: Escott
authors: Rhonan
authors: R
authors: Ford
authors: Ken
authors: K
authors: Grime
authors: Ian
authors: I
authors: Millichip
authors: Barry
authors: B
authors: Teobald
authors: Vince
authors: V
authors: Russell
mesh_terms: D001798:Blood Proteins / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D006801:Humans; D018727:Muscarinic Antagonists / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy; D011812:Quinuclidines / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D043587:Receptor, Muscarinic M3 / Q000819:agonists* / Q000378:metabolism; D013329:Structure-Activity Relationship
chemical_list: C570585:AZD9164; D001798:Blood Proteins; D018727:Muscarinic Antagonists; D010880:Piperidines; D011812:Quinuclidines; D043587:Receptor, Muscarinic M3